{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:32:32Z","timestamp":1793489552353,"version":"4.5.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that accounts for \u223c20% of ALL cases. Intensive chemotherapy regimens result in cure rates &amp;gt;85% in children and &amp;lt;50% in adults, warranting a search of novel therapeutic strategies. Although immune-based therapies have tremendously improved the treatment of B-ALL and other B-cell malignancies, they are not yet available for T-ALL. We report here that humanized, non\u2013Fc\u03b3 receptor (Fc\u03b3R)\u2013binding monoclonal antibodies (mAbs) to CD3 have antileukemic properties in xenograft (PDX) models of CD3+ T-ALL, resulting in prolonged host survival. We also report that these antibodies cooperate with chemotherapy to enhance antileukemic effects and host survival. Because these antibodies show only minor, manageable adverse effects in humans, they offer a new therapeutic option for the treatment of T-ALL. Our results also show that the antileukemic properties of anti-CD3 mAbs are largely independent of Fc\u03b3R-mediated pathways in T-ALL PDXs.<\/jats:p>","DOI":"10.1182\/blood.2019003801","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T02:51:10Z","timestamp":1591066270000},"page":"1298-1302","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Preclinical efficacy of humanized, non\u2013Fc\u03b3R-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1003-2626","authenticated-orcid":false,"given":"Christine","family":"Tran Quang","sequence":"first","affiliation":[{"name":"Institut Curie, Orsay, France;"},{"name":"Centre National de la Recherche Scientifique UMR3348, Centre Universitaire, Orsay, France;"},{"name":"UMR3348, University Paris Sud\u2013Paris-Saclay, Orsay, France;"},{"name":"UMR3348, PSL Research University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3807-9589","authenticated-orcid":false,"given":"Benedetta","family":"Zaniboni","sequence":"additional","affiliation":[{"name":"Institut Curie, Orsay, France;"},{"name":"Centre National de la Recherche Scientifique UMR3348, Centre Universitaire, Orsay, France;"},{"name":"UMR3348, University Paris Sud\u2013Paris-Saclay, Orsay, France;"},{"name":"UMR3348, PSL Research University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Humeau","sequence":"additional","affiliation":[{"name":"Institut Curie, Orsay, France;"},{"name":"Centre National de la Recherche Scientifique UMR3348, Centre Universitaire, Orsay, France;"},{"name":"UMR3348, University Paris Sud\u2013Paris-Saclay, Orsay, France;"},{"name":"UMR3348, PSL Research University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0965-6615","authenticated-orcid":false,"given":"Etienne","family":"Lenglin\u00e9","sequence":"additional","affiliation":[{"name":"Adult Leukemia Unit, Department of Hematology, H\u00f4pital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, University of Paris, Paris, France;"},{"name":"EA3518, Saint-Louis Research Institute, University of Paris, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Emilie","family":"Dourthe","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Immunology, H\u00f4pital Universitaire Robert-Debr\u00e9, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"},{"name":"INSERM U1151, Institut Necker-Enfants Malades, Universit\u00e9 Paris Descartes Sorbonne Cit\u00e9, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3431-9664","authenticated-orcid":false,"given":"Rajkumar","family":"Ganesan","sequence":"additional","affiliation":[{"name":"Janssen Biotherapeutics, Spring House, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjaya","family":"Singh","sequence":"additional","affiliation":[{"name":"Janssen Biotherapeutics, Spring House, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Scheer","sequence":"additional","affiliation":[{"name":"Boehringer-Ingelheim Pharmaceuticals, Inc, Ridgefield, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Asnafi","sequence":"additional","affiliation":[{"name":"INSERM U1151, Institut Necker-Enfants Malades, Universit\u00e9 Paris Descartes Sorbonne Cit\u00e9, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Ghysdael","sequence":"additional","affiliation":[{"name":"Institut Curie, Orsay, France;"},{"name":"Centre National de la Recherche Scientifique UMR3348, Centre Universitaire, Orsay, France;"},{"name":"UMR3348, University Paris Sud\u2013Paris-Saclay, Orsay, France;"},{"name":"UMR3348, PSL Research University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"27","key":"2020091011285015800_B1","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: Progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020091011285015800_B2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","article-title":"How I treat T-cell acute lymphoblastic leukemia in adults","volume":"126","author":"Litzow","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2020091011285015800_B3","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrc.2016.63","article-title":"The genetics and mechanisms of T cell acute lymphoblastic leukaemia","volume":"16","author":"Belver","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2020091011285015800_B4","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"issue":"11","key":"2020091011285015800_B5","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1080\/10428194.2019.1605071","article-title":"Recent advances in the treatment of acute lymphoblastic leukemia","volume":"60","author":"Rafei","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2020091011285015800_B6","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-15-0675","article-title":"Triggering the TCR developmental checkpoint activates a therapeutically targetable tumor suppressive pathway in T-cell leukemia","volume":"6","author":"Trinquand","year":"2016","journal-title":"Cancer Discov"},{"issue":"8","key":"2020091011285015800_B7","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/imt-2016-0049","article-title":"Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside","volume":"8","author":"Kuhn","year":"2016","journal-title":"Immunotherapy"},{"issue":"1","key":"2020091011285015800_B8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/cimm.2000.1617","article-title":"In vitro characterization of five humanized OKT3 effector function variant antibodies","volume":"200","author":"Xu","year":"2000","journal-title":"Cell Immunol"},{"issue":"11","key":"2020091011285015800_B9","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/00007890-199457110-00001","article-title":"A non-activating \u201chumanized\u201d anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo","volume":"57","author":"Alegre","year":"1994","journal-title":"Transplantation"},{"issue":"10","key":"2020091011285015800_B10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng Des Sel"},{"issue":"9","key":"2020091011285015800_B11","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","article-title":"Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice","volume":"292","author":"Lo","year":"2017","journal-title":"J Biol Chem"},{"issue":"7","key":"2020091011285015800_B12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes [published correction appears in N Engl J Med. 2020 Feb 6;382(6):586]","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2020091011285015800_B13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/00007890-199909150-00003","article-title":"Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection","volume":"68","author":"Woodle","year":"1999","journal-title":"Transplantation"},{"key":"2020091011285015800_B14","first-page":"w13711","article-title":"Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases","volume":"142","author":"Dean","year":"2012","journal-title":"Swiss Med Wkly"},{"issue":"6","key":"2020091011285015800_B15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ccell.2015.05.003","article-title":"CXCR4 is required for leukemia-initiating cell activity in T cell acute lymphoblastic leukemia","volume":"27","author":"Passaro","year":"2015","journal-title":"Cancer Cell"},{"key":"2020091011285015800_B16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.0105-2896.2006.00358.x","article-title":"TCR and Notch signaling in CD4 and CD8 T-cell development","volume":"209","author":"Laky","year":"2006","journal-title":"Immunol Rev"},{"issue":"18","key":"2020091011285015800_B17","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1128\/MCB.20.18.6945-6957.2000","article-title":"Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation","volume":"20","author":"Shan","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"10","key":"2020091011285015800_B18","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/ibd.21252","article-title":"Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn\u2019s disease","volume":"16","author":"van der Woude","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2020091011285015800_B19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.clim.2009.04.007","article-title":"Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years","volume":"132","author":"Herold","year":"2009","journal-title":"Clin Immunol"},{"issue":"11","key":"2020091011285015800_B20","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.2337\/db13-0236","article-title":"Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Prot\u00e9g\u00e9 trial","volume":"62","author":"Hagopian","year":"2013","journal-title":"Diabetes"},{"key":"2020091011285015800_B21","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"2020091011285015800_B22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"issue":"13","key":"2020091011285015800_B23","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1182\/blood-2017-01-764316","article-title":"An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts","volume":"130","author":"Schewe","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020091011285015800_B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2017-10-798769","article-title":"Introduction to a review series on therapeutic antibodies","volume":"131","author":"Stevenson","year":"2018","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/11\/1298\/1757300\/bloodbld2019003801.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/11\/1298\/1757300\/bloodbld2019003801.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T16:13:24Z","timestamp":1599754404000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/11\/1298\/460600\/Preclinical-efficacy-of-humanized-nonFc%CE%B3Rbinding"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003801","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]}}}